Home › Companies › BEAM THERAPEUTICS INC. › 2024-2025

BEAM THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BEAM THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
275Asset managers
1,407Fund votes
June 4, 2025Meeting date

Results at a glance

Meeting of June 4, 2025: 5 items on BEAM THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 3 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BEAM THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BEAM THERAPEUTICS INC.

These tallies are BEAM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BEAM THERAPEUTICS INC. — official shareholder meeting results, meeting held June 4, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Mark Fishman, M.D.	61,949,019	10,285,110	63,755	--	12,201,172	86%	Elected	—
Elect Director: Carole Ho, M.D.	71,720,651	548,021	29,212	--	12,201,172	99.2%	Elected	—
Elect Director: Kathleen Walsh	71,888,413	379,636	29,835	--	12,201,172	99.4%	Elected	—
2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025	84,281,031	154,426	63,599	--	--	99.8%	Approved	—
3. Compensation of the Company's named executive officers	71,701,062	562,871	33,951	--	12,201,172	99.2%	Approved	—

Source: BEAM THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.

How asset managers voted at the BEAM THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 275 asset managers that disclosed a BEAM THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Carole Ho, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 71,720,651AGAINST: 548,021

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Carole Ho, M.D.

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carole Ho, M.D.”): 71,720,651 for, 548,021 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 29,460,705 for, 126,726 against, 5,512 abstained.

FOR

FOR: 29,460,705AGAINST: 126,726ABSTAIN: 5,512

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,828	0	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	Mixed
JPMorgan	240,632	0	0	For
TIAA	196,720	0	0	For
State Street	181,385	0	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	132,736	0	0	For
Pacific Life	130,302	0	0	For
Lincoln Financial	99,381	3,184	0	For
American Century	99,408	0	0	For
AIG/SunAmerica	74,839	0	0	For
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	60,077	0	0	For
Brighthouse	50,497	0	5,512	Mixed
Transamerica	55,500	0	0	For
MFS	55,346	0	0	For
Northern Trust	54,062	0	0	For
WisdomTree	51,544	0	0	For
Bridge Builder Trust	50,557	0	0	For
ProShares	45,776	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

2. Elect Director: Kathleen Walsh

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 71,888,413AGAINST: 379,636

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Kathleen Walsh

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathleen Walsh”): 71,888,413 for, 379,636 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 29,460,705 for, 126,726 against, 5,512 abstained.

FOR

FOR: 29,460,705AGAINST: 126,726ABSTAIN: 5,512

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,828	0	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	Mixed
JPMorgan	240,632	0	0	For
TIAA	196,720	0	0	For
State Street	181,385	0	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	132,736	0	0	For
Pacific Life	130,302	0	0	For
Lincoln Financial	99,381	3,184	0	For
American Century	99,408	0	0	For
AIG/SunAmerica	74,839	0	0	For
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	60,077	0	0	For
Brighthouse	50,497	0	5,512	Mixed
Transamerica	55,500	0	0	For
MFS	55,346	0	0	For
Northern Trust	54,062	0	0	For
WisdomTree	51,544	0	0	For
Bridge Builder Trust	50,557	0	0	For
ProShares	45,776	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

3. Elect Director: Mark Fishman, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST

FOR: 61,949,019AGAINST: 10,285,110

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Mark Fishman, M.D.

BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Fishman, M.D.”): 61,949,019 for, 10,285,110 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class II directors to serve on the Company's board of directors until the Company's 2028 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 28,771,445 for, 815,986 against, 5,512 abstained.

FOR

FOR: 28,771,445AGAINST: 815,986ABSTAIN: 5,512

Largest asset managers voting on “Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of ” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,066	762	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	185,069	86,610	0	Mixed
JPMorgan	240,632	0	0	For
TIAA	196,720	0	0	For
State Street	181,213	172	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	0	132,736	0	Against
Pacific Life	130,302	0	0	For
Lincoln Financial	86,221	16,344	0	Mixed
American Century	0	99,408	0	Against
AIG/SunAmerica	0	74,839	0	Against
Yiheng Capital Management, L.P.	69,058	0	0	For
John Hancock	27,958	32,119	0	Mixed
Brighthouse	44,518	5,979	5,512	Mixed
Transamerica	55,500	0	0	For
MFS	0	55,346	0	Against
Northern Trust	0	54,062	0	Against
WisdomTree	0	51,544	0	Against
Bridge Builder Trust	42,882	7,675	0	Mixed
ProShares	0	45,776	0	Against

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

4. 3. Compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

99.2% Approved · of votes cast

FOR 99.2%

FOR: 71,701,062AGAINST: 562,871

Details: description as filed, official tally, votes by 275 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.

BEAM THERAPEUTICS INC.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 71,701,062 for, 562,871 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 62 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	8,716,828	0	0	For
ARK ETF Trust	7,995,179	0	0	For
Fidelity	4,653,310	0	0	For
BlackRock	2,784,446	0	0	For
T. Rowe Price	2,272,505	0	0	For
Charles Schwab	783,402	0	0	For
Equitable	271,679	0	0	For
JPMorgan	240,632	0	0	For
TIAA	196,720	0	0	For
State Street	181,379	6	0	For
Global X	141,913	0	0	For
JANUS INVESTMENT FUND	132,736	0	0	For
Pacific Life	130,302	0	0	For
Lincoln Financial	102,565	0	0	For
American Century	99,408	0	0	For
AIG/SunAmerica	74,839	0	0	For
John Hancock	60,077	0	0	For
Brighthouse	50,497	0	5,512	Mixed
Transamerica	55,500	0	0	For
MFS	55,346	0	0	For
Northern Trust	54,062	0	0	For
WisdomTree	51,544	0	0	For
Bridge Builder Trust	42,882	7,675	0	Mixed
ProShares	45,776	0	0	For
ARK Venture Fund	36,860	0	0	For

Fund voting reports, all 62 managers: 29,510,002 for, 8,371 against, 5,512 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 227 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Withheld	Vote
FARALLON CAPITAL MANAGEMENT LLC	8,056,102	0	0	For
Fidelity	4,952,230	0	0	For
ARCH Venture Management, LLC	4,540,132	0	0	For
Nikko Asset Management Co., Ltd.	4,433,768	0	0	For
BlackRock	2,909,856	0	0	For
T. Rowe Price	2,832,540	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,954,882	0	0	For
Temasek Holdings (Private) Ltd	1,812,972	0	0	For
State Street	1,546,507	7,495	0	For
Redmile Group, LLC	1,527,342	0	0	For
Impresa Management LLC	1,139,443	0	0	For
Charles Schwab	783,595	0	0	For
Woodline Partners LP	760,611	0	0	For
JPMorgan	680,573	0	0	For
Avidity Partners Management LP	559,517	0	0	For
EcoR1 Capital, LLC	526,685	0	0	For
Northern Trust	434,943	0	0	For
Janus Henderson	433,883	0	0	For
RTW INVESTMENTS, LP	424,248	0	0	For
Kynam Capital Management, LP	0	0	291,041	Withhold
Vanguard	259,311	0	0	For
Citadel	226,406	0	0	For
ARK Investment Management LLC	209,642	0	0	For
Casdin Capital, LLC	201,205	0	0	For
Nuveen	199,880	0	0	For

Institutional-manager reports, all 227 managers: 44,280,209 for, 312,460 against, 291,041 withheld, 1,384 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.

5. 2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

99.8% Approved · of votes cast

FOR 99.8%

FOR: 84,281,031AGAINST: 154,426

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

BEAM THERAPEUTICS INC.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025”): 84,281,031 for, 154,426 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 29,586,741 for, 690 against, 5,512 abstained.

FOR

FOR: 29,586,741AGAINST: 690ABSTAIN: 5,512

Largest asset managers voting on “RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR F” at BEAM THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	8,716,828	0	For
ARK ETF Trust	7,995,179	0	For
Fidelity	4,653,310	0	For
BlackRock	2,784,446	0	For
T. Rowe Price	2,272,505	0	For
Charles Schwab	783,402	0	For
Equitable	271,679	0	For
JPMorgan	240,632	0	For
TIAA	196,720	0	For
State Street	181,385	0	For
Global X	141,913	0	For
JANUS INVESTMENT FUND	132,736	0	For
Pacific Life	130,302	0	For
Lincoln Financial	102,565	0	For
American Century	99,408	0	For
AIG/SunAmerica	74,839	0	For
Yiheng Capital Management, L.P.	69,058	0	For
John Hancock	60,077	0	For
Brighthouse	50,497	5,512	Mixed
Transamerica	55,500	0	For
MFS	55,346	0	For
Northern Trust	54,062	0	For
WisdomTree	51,544	0	For
Bridge Builder Trust	50,557	0	For
ProShares	45,776	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

Largest BEAM THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 100,557,094 shares outstanding at the time of that meeting.

Fund voting reports: top BEAM THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	8.67%
2	ARK ETF Trust	7.95%
3	Fidelity	4.63%
4	BlackRock	2.77%
5	T. Rowe Price	2.26%
6	Charles Schwab	0.78%
7	Equitable	0.27%
8	JPMorgan	0.24%
9	TIAA	0.20%
10	State Street	0.18%

Institutional-manager reports: top BEAM THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	FARALLON CAPITAL MANAGEMENT LLC	8.01%
2	Fidelity	4.92%
3	ARCH Venture Management, LLC	4.51%
4	Nikko Asset Management Co., Ltd.	4.41%
5	BlackRock	2.89%
6	T. Rowe Price	2.82%
7	GEODE CAPITAL MANAGEMENT, LLC	1.94%
8	Temasek Holdings (Private) Ltd	1.80%
9	State Street	1.55%
10	Redmile Group, LLC	1.52%

Reported BEAM THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

BEAM THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	12.40%	13G
FMR LLC and affiliates	9.99%	DEF14A
Farallon Partners, L.L.C.	9.75%	13G
Farallon Capital Partners and affiliates	9.59%	DEF14A
Vanguard Group	8.82%	13F
BlackRock	8.06%	13F
FMR (Fidelity)	7.88%	13F
State Street	3.42%	13F
T. Rowe Price	3.01%	13F
Citadel Advisors	2.69%	13F

Percentages above are of 100,557,094 shares outstanding, as reported by BEAM THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BEAM THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At BEAM THERAPEUTICS INC.'s shareholder meeting held June 4, 2025, in the 2024-2025 proxy season, 275 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,407 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — BEAM THERAPEUTICS INC.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BEAM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.

BEAM THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.